Skip to Content

Dexferrum (iron dextran) Disease Interactions

There are 6 disease interactions with Dexferrum (iron dextran):

Major

Ferrous salts (applies to Dexferrum) hemoglobin abnormalities

Major Potential Hazard, High plausibility. Applicable conditions: Blood Transfusion, Hemoglobinopathy

There is no excretory mechanism for iron. Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions. Clinical monitoring of erythropoietic function and ferritin levels is recommended.

References

  1. "Product Information. INFeD (iron dextran)." Schein Pharmaceuticals Inc, Florham Park, NJ.
Major

Iron dextran (applies to Dexferrum) hepatic dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Liver Disease

Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver. Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes. Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.

References

  1. "Product Information. INFeD (iron dextran)." Schein Pharmaceuticals Inc, Florham Park, NJ.
Major

Iron dextran (applies to Dexferrum) nervous system dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Neurologic Disorder, Seizures

Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness. Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.

References

  1. "Product Information. INFeD (iron dextran)." Schein Pharmaceuticals Inc, Florham Park, NJ.
  2. Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982): 248-9
  3. Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990): 162-6
Moderate

Iron dextran (applies to Dexferrum) cardiovascular dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease

Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy. Hypotension and flushing have been reported and are thought to be infusion- rate related. Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.

References

  1. "Product Information. INFeD (iron dextran)." Schein Pharmaceuticals Inc, Florham Park, NJ.
  2. Shimada A "Adverse reactions to total-dose infusion of iron dextran." Clin Pharm 1 (1982): 248-9
Moderate

Iron dextran (applies to Dexferrum) hypersensitivity reactions

Moderate Potential Hazard, High plausibility. Applicable conditions: Allergies, Asthma

Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration. Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma. Epinephrine should be immediately available in the event of acute hypersensitivity reactions.

References

  1. Amitai A, Acker M "Adverse effects of intramuscular iron injection." Acta Haematol 68 (1982): 341-2
  2. Jacobs J "Death due to iron parenterally." South Med J 62 (1969): p216assim
  3. Altman LC, Petersen PE "Successful prevention of an anaphylactoid reaction to iron dextran." Ann Intern Med 109 (1988): 346-7
  4. Berliner S, Shoenfeld Y, Livni E, Pinkhas J "Allergic purpura following intravenous administration of iron dextran." Acta Haematol 62 (1979): 178
  5. Becker CE, MacGregor RR, Walker KS, Jandl JH "Fatal anaphylaxis after intramuscular iron-dextran." Ann Intern Med 65 (1966): 745-8
  6. Zipf RE Jr "Fatal anaphylaxis after intravenous iron dextran." J Forensic Sci 20 (1975): 326-33
  7. Bielory L "Serum sickness from iron-dextran administration." Acta Haematol 83 (1990): 166-8
  8. Hart GD, Soots M "An anaphylactic reaction complicating total dose infusion therapy of iron deficiency." Appl Ther 11 (1969): 645-6
  9. Kumpf VJ, Holland EG "Parenteral iron dextran therapy." DICP 24 (1990): 162-6
  10. "Product Information. INFeD (iron dextran)." Schein Pharmaceuticals Inc, Florham Park, NJ.
View all 10 references
Minor

Iron dextran (applies to Dexferrum) rheumatoid arthritis

Minor Potential Hazard, Moderate plausibility.

Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.

Dexferrum (iron dextran) drug interactions

There are 26 drug interactions with Dexferrum (iron dextran)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.